These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 22302659)
1. The Role of Regulatory T Cells in Mesothelioma. Ireland DJ; Kissick HT; Beilharz MW Cancer Microenviron; 2012 Aug; 5(2):165-72. PubMed ID: 22302659 [TBL] [Abstract][Full Text] [Related]
2. Local effector failure in mesothelioma is not mediated by CD4+ CD25+ T-regulator cells. Jackaman C; Cornwall S; Lew AM; Zhan Y; Robinson BW; Nelson DJ Eur Respir J; 2009 Jul; 34(1):162-75. PubMed ID: 19251786 [TBL] [Abstract][Full Text] [Related]
3. Tumour eradication and induction of memory against murine mesothelioma by combined immunotherapy. Kissick HT; Ireland DJ; Krishnan S; Madondo M; Beilharz MW Immunol Cell Biol; 2012 Sep; 90(8):822-6. PubMed ID: 22349521 [TBL] [Abstract][Full Text] [Related]
4. Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy? Jacobs JF; Nierkens S; Figdor CG; de Vries IJ; Adema GJ Lancet Oncol; 2012 Jan; 13(1):e32-42. PubMed ID: 22225723 [TBL] [Abstract][Full Text] [Related]
5. [Anti-tumor immunotherapy in malignant pleural mesothelioma]. Scherpereel A; Willemin MC; Wasielewski E; Dhalluin X Rev Mal Respir; 2018 Apr; 35(4):465-476. PubMed ID: 29415822 [TBL] [Abstract][Full Text] [Related]
7. Combination immune checkpoint blockade as an effective therapy for mesothelioma. Fear VS; Tilsed C; Chee J; Forbes CA; Casey T; Solin JN; Lansley SM; Lesterhuis WJ; Dick IM; Nowak AK; Robinson BW; Lake RA; Fisher SA Oncoimmunology; 2018; 7(10):e1494111. PubMed ID: 30288361 [TBL] [Abstract][Full Text] [Related]
8. Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma. DeLong P; Carroll RG; Henry AC; Tanaka T; Ahmad S; Leibowitz MS; Sterman DH; June CH; Albelda SM; Vonderheide RH Cancer Biol Ther; 2005 Mar; 4(3):342-6. PubMed ID: 15846066 [TBL] [Abstract][Full Text] [Related]
9. Effective immunotherapy of weakly immunogenic solid tumours using a combined immunogene therapy and regulatory T-cell inactivation. Whelan MC; Casey G; MacConmara M; Lederer JA; Soden D; Collins JK; Tangney M; O'Sullivan GC Cancer Gene Ther; 2010 Jul; 17(7):501-11. PubMed ID: 20186173 [TBL] [Abstract][Full Text] [Related]
10. Low-dose cyclophosphamide depletes circulating naïve and activated regulatory T cells in malignant pleural mesothelioma patients synergistically treated with dendritic cell-based immunotherapy. Noordam L; Kaijen MEH; Bezemer K; Cornelissen R; Maat LAPWM; Hoogsteden HC; Aerts JGJV; Hendriks RW; Hegmans JPJJ; Vroman H Oncoimmunology; 2018; 7(12):e1474318. PubMed ID: 30524884 [No Abstract] [Full Text] [Related]
11. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Finn OJ Ann Oncol; 2012 Sep; 23 Suppl 8(Suppl 8):viii6-9. PubMed ID: 22918931 [TBL] [Abstract][Full Text] [Related]
12. Targeting the inhibitory receptor CTLA-4 on T cells increased abscopal effects in murine mesothelioma model. Wu L; Wu MO; De la Maza L; Yun Z; Yu J; Zhao Y; Cho J; de Perrot M Oncotarget; 2015 May; 6(14):12468-80. PubMed ID: 25980578 [TBL] [Abstract][Full Text] [Related]
13. New roads open up for implementing immunotherapy in mesothelioma. Cornelissen R; Heuvers ME; Maat AP; Hendriks RW; Hoogsteden HC; Aerts JG; Hegmans JP Clin Dev Immunol; 2012; 2012():927240. PubMed ID: 22778767 [TBL] [Abstract][Full Text] [Related]
14. Synergistic antitumor effects of regulatory T cell blockade combined with pemetrexed in murine malignant mesothelioma. Anraku M; Tagawa T; Wu L; Yun Z; Keshavjee S; Zhang L; Johnston MR; de Perrot M J Immunol; 2010 Jul; 185(2):956-66. PubMed ID: 20548032 [TBL] [Abstract][Full Text] [Related]
15. Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma. Bensaid D; Blondy T; Deshayes S; Dehame V; Bertrand P; Grégoire M; Errami M; Blanquart C Clin Epigenetics; 2018; 10():79. PubMed ID: 29946373 [TBL] [Abstract][Full Text] [Related]
16. Overexpression and potential targeting of the oncofoetal antigen 5T4 in malignant pleural mesothelioma. Al-Taei S; Salimu J; Lester JF; Linnane S; Goonewardena M; Harrop R; Mason MD; Tabi Z Lung Cancer; 2012 Aug; 77(2):312-8. PubMed ID: 22498111 [TBL] [Abstract][Full Text] [Related]
17. Immunotherapies for non-small-cell lung cancer and mesothelioma. Thomas A; Hassan R Lancet Oncol; 2012 Jul; 13(7):e301-10. PubMed ID: 22748269 [TBL] [Abstract][Full Text] [Related]
18. Phenotypic alterations, clinical impact and therapeutic potential of regulatory T cells in cancer. Chaudhary B; Abd Al Samid M; al-Ramadi BK; Elkord E Expert Opin Biol Ther; 2014 Jul; 14(7):931-45. PubMed ID: 24661020 [TBL] [Abstract][Full Text] [Related]
19. The role of regulatory T lymphocytes in the induced immune response mediated by biological vaccines. López M; Aguilera R; Pérez C; Mendoza-Naranjo A; Pereda C; Ramirez M; Ferrada C; Aguillón JC; Salazar-Onfray F Immunobiology; 2006; 211(1-2):127-36. PubMed ID: 16446177 [TBL] [Abstract][Full Text] [Related]
20. Tumor cell repopulation between cycles of chemotherapy is inhibited by regulatory T-cell depletion in a murine mesothelioma model. Wu L; Yun Z; Tagawa T; Rey-McIntyre K; Anraku M; de Perrot M J Thorac Oncol; 2011 Sep; 6(9):1578-86. PubMed ID: 21642867 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]